Agnieszka
Agnieszka Ambrozak, Buchs CH
Patent application number | Description | Published |
---|---|---|
20090186913 | Tetrahalogenated compounds useful as inhibitors of angiogenesis - Methods for inhibiting a neoplasm in a subject and methods of inhibiting undesired angiogenesis that include administering to a subject a therapeutically effective amount of at least one novel tetrahalogenated compound, or a pharmaceutically acceptable salt thereof. | 07-23-2009 |
Agnieszka Beczala, Borstel DE
Patent application number | Description | Published |
---|---|---|
20150139998 | NOVEL CELL WALL POLYMERS OF ENTEROCOCCUS FAECALIS AND USES THEREOF - The present invention relates to enterococcal cell wall polymers and their uses in the prevention and therapy of bacterial infection. | 05-21-2015 |
Agnieszka Bialkowska, East Setauket, NY US
Patent application number | Description | Published |
---|---|---|
20150246908 | KLF5 MODULATORS - The invention provides potent inhibitors of small molecule inhibitors of Krüppel-like factor 5 (KLF5) expression. Compounds of the invention are small molecule inhibitors of KLF5 expression which can be effective delay or prevent colon cancer onset, halt growth of existing tumors, and/or decrease reoccurrence. The compounds can be effective vs. many tumor types whose progression is in part mediated by KLF5, including colorectal cancers. Lowering KLF5 levels with an inhibitor of this invention may also impact other disease states, including diabetes, obesity, lipid homeostasis, cardiovascular disease, and arthritis. | 09-03-2015 |
Agnieszka Brandt, London, Greater London GB
Patent application number | Description | Published |
---|---|---|
20160040354 | Treatment - The present invention relates to an improved method for treating a lignocellulose biomass in order to dissolve the lignin therein, while the cellulose does not dissolve. The cellulose pulp obtained can be used to produce glucose. In addition the lignin can be isolated for subsequent use in the renewable chemical industry as a source for aromatic platform chemicals. | 02-11-2016 |
Agnieszka Burzynska, Zawiercie PL
Patent application number | Description | Published |
---|---|---|
20080214876 | Process for Preparation of Pharmaceutically Pure Anhydrous Calcipotriol - A process for the preparation of a pharmaceutical-grade anhydrous calcipotriol comprising: (a) dissolving crude calcipotriol having a water content of X % by weight in a first solvent or in a mixture of two or more first solvents, said first solvent or said mixture of two or more first solvents forming an azeotropic system with water, to obtain a solution of crude calcipotriol; (b) obtaining an intermediate calcipotriol by (i) placing said solution of crude calcipotriol under a reduced pressure and evaporating, if X is greater than or equal to 1, or (ii) crystallizing, if X is lower than 1; and (c) re-dissolving said intermediate calcipotriol in a second solvent or a mixture of two or more second solvents, said second solvent being anhydrous, and crystallizing at least once to obtain pharmaceutical-grade anhydrous calcipotriol. | 09-04-2008 |
Agnieszka Ciesielska, Warszawa PL
Patent application number | Description | Published |
---|---|---|
20090105483 | PROCESS FOR THE PREPARATION OF PRAMIPEXOLE BASE AND/OR ITS SALTS - The process for the preparation of pramipexole base and/or its pharmaceutically acceptable salts, especially the hydrochloride salt, in the alkylation reaction of (S)-(−)2,6-diamino-4,5,6,7-tetrahydrobenzothiazole with an alkylating agent, wherein the reaction is carried out in the absence of a base, and in a solvent from which the resulting N-monoalkylated product selectively precipitates out as a salt. After isolation from the reaction mixture, the N-monoalkylated product is converted a) into the free pramipexole base upon treatment with an inorganic base and is then converted into another pharmaceutically acceptable pramipexole salt; or b) directly into another pharmaceutically acceptable pramipexole salt or the hydrate thereof. | 04-23-2009 |
Agnieszka Czechowicz, Menlo Park, CA US
Patent application number | Description | Published |
---|---|---|
20100226927 | SELECTIVE IMMUNODEPLETION OF ENDOGENOUS STEM CELL NICHE FOR ENGRAFTMENT - The present invention provides a clinically applicable method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring radiotherapy or chemotherapy, and without development of GVHD or graft rejection. Aspects of the present invention are based on the discovery that the depletion of the endogenous stem cell niche facilitates efficient engraftment of stem cells into that niche. In particular, the present invention combines the use of selective ablation of endogenous stem cells, in combination with the administration to the recipient of exogenous stem cells, resulting in efficient, long-term engraftment and tolerance. | 09-09-2010 |
Agnieszka Dreas, Poznan PL
Patent application number | Description | Published |
---|---|---|
20150274726 | SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS - Disclosed are substituted tricyclic benzimidazoles compounds as defined herein in formula (I) or pharmaceutically acceptable salts thereof. The compounds of the invention selectively inhibit CDK8 and are therefore useful for treating diseases related to this kinase, especially colorectal and melanoma cancers and other solid and hemathological malignancies, autoimmune diseases and inflammatory diseases. Also disclosed are processes for preparing these compounds. | 10-01-2015 |
Agnieszka Dryla, Vienna AT
Patent application number | Description | Published |
---|---|---|
20110020402 | Method For Identification, Isolation And Production Of Antigens To A Specific Pathogen - Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:—providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogren, tumor, allergen or tissue or host prone to auto-immunity,—providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—screening said at least one expression library with said antibody preparation, identifying antigens which bind in said screening to antibodies in said antibody preparation, —screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and—optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods. | 01-27-2011 |
20130034575 | METHOD FOR IDENTIFICATION, ISOLATION AND PRODUCTION OF ANTIGENS TO A SPECIFIC PATHOGEN - Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: providing an antibody preparation, providing at least one expression library, identifying antigens which bind, screening the identified antigens, identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods. | 02-07-2013 |
Agnieszka Dybowska, London GB
Patent application number | Description | Published |
---|---|---|
20120282645 | NANOPARTICLES - Nanoparticles, compositions comprising the nanoparticles, and methods for manufacture and uses thereof are provided. In at least one specific embodiment, the nanoparticle can include at least one isotopically enriched metal oxide. The isotopically enriched metal oxide can be copper or zinc. | 11-08-2012 |
Agnieszka Fedoruk-Wyszomirska, Poznan PL
Patent application number | Description | Published |
---|---|---|
20120322755 | CYTOSINE ANALOGUE, A METHOD OF PREPARATION OF A CYTOSINE ANALOGUE, A DNA METHYLTRANSFERASE 1 INHIBITOR, A METHOD FOR DNA METHYLATION INHIBITION, THE USE OF THE ANALOGUE IN THE TREATMENT OF DISEASES ASSOCIATED WITH DEVIATIONS FROM NORMAL DNA METHYLATION - This invention provides a cytosine analogue, a method of preparation of a cytosine analogue, a DNA rhethyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated with deviations from normal DNA methylation. More precisely, the invention relates to various derivatives of cytosine, as well as methods of preparation of mono- and multi-1,4,5 and 6-substituted cytosines. In general, the solution relates to providing effective modulators of DNA methylation which could be used in prevention and treatment of diseases associated with DNA methylation level disorders. | 12-20-2012 |
20160046938 | HAMMERHEAD RIBOZYMES - The object of the invention are hammerhead ribozymes directed against the sequence of miR-21 and/or miR-21 precursors, having the ability to specifically cleave miR-21 and/or miR-21 precursors, and wherein they have a catalytic core with a sequence as shown in SEQ ID No 1. The invention also relates to a composition comprising such ribozymes, a therapeutic agent comprising them, a use of such ribozymes and a method of selective cleavage of miR-21 and/or miR-21 precursors employing such ribozymes. | 02-18-2016 |
Agnieszka Gielara-Korzanska, Tulce PL
Patent application number | Description | Published |
---|---|---|
20150080583 | QUATERNARY AMMONIUM SALTS, METHOD FOR PREPARATION AND APPLICATIONS THEREOF - The invention relates to a novel class of quaternary ammonium salts containing tetra-hydro[1,3]oxazolo[2,3-b][1,3]oxazol-4-ium moiety in the structure, in particular the new derivatives of 4-methyltetrahydro[1,3]oxazolo[2,3-b][1,3]oxazol-4-ium, 4-(2-oxoethyl)tetrahydro[1,3]oxazolo[2,3-6][1,3]oxazol-4-ium, bis{4-methyltetrahydro[1,3]oxazoio[2,3-6][1,3]oxazol-4-ium}, bis{4-(2-oxoethyl)tetrahydro[1,3]oxazolo[2,3-b][1,3]oxazol-4-ium} and tris{4-methyltetrahydro[1,3]oxazolo[2,3-b][1,3]oxazol-4-ium} salts, process for the preparation of a novel class of quaternary ammonium salts and applications thereof. | 03-19-2015 |
Agnieszka Gladka, Lowicz PL
Patent application number | Description | Published |
---|---|---|
20120283495 | METHOD AND A DEVICE FOR GENERATING A CARBURIZING GAS MIXTURE - A method to generate a ternary carburizing gas mixture, using a reaction of selective hydrogenation of acetylene in a stream of hydrocarbons to the form of ethylene, comprising the following steps: heating of the inside of the reactor with an inert gas to an operating temperature for a period of 20 minutes at a temperature of 300° K, passing a mixture of hydrogen and acetylene by the regiospecific catalyst, and moving out the reaction products on the outside after passing the mixture through the regiospecific catalyst, but generation is effected in a continuous mode in the operating temperature range of the regiospecific catalyst between 293° K and 398° K, preferably at a temperature of 350° K. | 11-08-2012 |
Agnieszka Glebocka, Warsaw PL
Patent application number | Description | Published |
---|---|---|
20090281340 | 1ALPHA-HYDROXY-2-(3'-HYDROXYPROPYLIDENE)-19-NOR-VITAMIN D COMPOUNDS AND METHODS OF MAKING AND TREATMENT THEREOF - Disclosed are 1α-hydroxy-2-(3′-hydroxypropylidene)-19-nor-vitamin D compounds, pharmaceutical compositions, and methods of making and treatment thereof. The compounds are generally directed to biologically active 2-alkylidene-19-nor-vitamin D compounds and analogs thereof characterized by the presence of a 3′-hydroxypropylidene moiety at C-2 and the presence of an abbreviated alkyl side-chain free of any hydroxyl moiety. | 11-12-2009 |
Agnieszka Glebocka, Madison, WI US
Patent application number | Description | Published |
---|---|---|
20090170822 | 2-Methylene-20-Methyl-19,24,25,26,27-Pentanor-Vitamin D Analogs - This invention discloses 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin D analogs, and specifically 2-methylene-20-methyl-1α-hydroxy-19,24,25,26,27-pentanor-vitamin D | 07-02-2009 |
20100009944 | 19-Nor-Vitamin D Analogs with 1,2-Dihydrofuran Ring - 19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, secondary hyperparathyroidism, psoriasis, or other skin diseases. | 01-14-2010 |
20100009945 | 19-NOR-VITAMIN D ANALOGS WITH 3,2-DIHYDROFURAN RING - 19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 3β-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, metabolic bone diseases, osteomalacia, osteopenia, secondary hyperparathyroidism, psoriasis, or other skin diseases. | 01-14-2010 |
20110082122 | 19-Nor-Vitamin D Analogs With 1,2- or 3,2-Cyclopentene Ring - 19-nor-vitamin D analogs having an additional cyclopentene ring connecting carbon 1 and carbon 2, or connecting carbon 3 and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro activities, making them therapeutic agents for the treatment or prophylaxis of some types of cancers, particularly leukemia, colon cancer, breast cancer, skin cancer or prostate cancer. | 04-07-2011 |
20130053356 | 2-METHYLENE-19,23,24-TRINOR-1ALPHA-HYDROXYVITAMIN D3 - Compounds of Formula I are provided where R | 02-28-2013 |
20130053587 | Crystallization of 1alpha-Hydroxy-20-Methyl-2-Methylene-19,24,25,26,27-Pentanorvitamin D3 - A method of purifying 1α-hydroxy-20-methyl-2-methylene-19,24,25,26,27-pentanorvitamin D | 02-28-2013 |
20130331459 | A-Ring Modified 19-Nor-Vitamin D Analogs and Their Uses - Disclosed are 19-nor-vitamin D compounds, and specifically seco-A-2,19-dinor-1,25-dihydroxyvitamin D | 12-12-2013 |
20140011778 | 2-METHYLENE-19,23,24-TRINOR-1ALPHA-HYDROXYVITAMIN D3 - Compounds of Formula I are provided where R | 01-09-2014 |
Agnieszka Gozdek, Warsaw PL
Patent application number | Description | Published |
---|---|---|
20150192569 | METHOD OF EVALUATING THE THERAPEUTIC EFFICACY OF BACTERIOPHAGES - The subject of the present invention is a novel use of a nematode in the evaluation of the therapeutic efficacy of bacteriophage preparations used in, or capable of being used in the treatment of infections caused by pathogenic bacteria in humans or animals. | 07-09-2015 |
Agnieszka Hanulak, Birmingham, MI US
Patent application number | Description | Published |
---|---|---|
20110070566 | Meal Planning System - A meal planning system may include first, second and third grocery lists, a plurality of first recipes and a plurality of second recipes. The second grocery list may be associated with the first grocery list. The first recipes may be associated with the second grocery list. Each of the first recipes may include food items from at least one of the first and second grocery lists. The second grocery list includes enough food items to prepare the first recipes. The third grocery list may be associated with the first grocery list. The second recipes may be associated with the third grocery list. Each of the second recipes may include food items from at least one of the first and third grocery lists. The third grocery list includes enough food items to prepare the second recipes. The grocery lists and recipes may be displayed on cards and/or an electronic device. | 03-24-2011 |
Agnieszka Jeziorska, Thonon-Les-Bains FR
Patent application number | Description | Published |
---|---|---|
20150321826 | SELF COLLAPSABLE BLOW MOULDED PLASTIC THIN-WALLED CONTAINERS, THEIR MANUFACTURING PROCESS AND THEIR APPLICATIONS IN WATER DISPENSING UNITS - The invention pertains to self collapsable blow moulded plastic thin-walled PET bottle ( | 11-12-2015 |
Agnieszka Kierzkowska, Polkowice PL
Patent application number | Description | Published |
---|---|---|
20110087286 | UNLOADING D-DYNAMIC INTERVERTEBRAL DEVICE - An unloading dynamic intervertebral device comprising a first bar and a second bar configured for providing an even, steady and adjustable decompression of the intervertebral interspinous space and for maintaining the distance between at least two vertebrae. The first bar may comprise a guideline with an elongated gap formed therein. The second bar may comprise a guide having at least one tang interposed within the elongated gap of the first bar, such that the first bar and the second bar are rotationally and slidably connected with each other about the tang. An end of the first bar and an opposing end of the second bar may comprise shaped bearings configured for bony elements of the spine. The first and second bar may be movable relative to each other between an open position and a closed position. | 04-14-2011 |
Agnieszka Konczykowska, Marcoussis FR
Patent application number | Description | Published |
---|---|---|
20130202316 | OPTOELECTRONIC DEVICE FOR DIFFERENTIAL PHOTORECEPTION, WITH AUTOMATIC COMPENSATION OF PHASE AND AMPLITUDE IMBALANCES - An optoelectronic device includes a photodetection means arranged for converting first and second complementary optical signals into first and second complementary currents, and a processing means arranged for processing these first and second complementary currents to output at least a first output voltage. This processing means includes i) a conversion means arranged for separately converting the first and second complementary currents into first and second operating voltages, ii) a balancing means arranged for balancing phase and amplitude of the first and second operating voltages, and iii) a differential amplification means arranged for applying a subtraction function to the first and second operating voltages with balanced phase and amplitude to produce at least the first output voltage, which is proportional to the difference between the first and second operating voltages with balanced phase and amplitude. | 08-08-2013 |
Agnieszka Kopciuch, Ligota Piekna PL
Patent application number | Description | Published |
---|---|---|
20130295647 | METHOD OF PRODUCING BACTERIOPHAGE PREPARATIONS COMPRISING PURIFICATION USING AFFINITY CHROMATOGRAPHY - The proposed method facilitates the single-stage and at the same time effective purification of phage preparations for therapeutic uses, and facilitates the maintenance of bacteriophage antibacterial activity both in the case of displacement of the bacteriophage from the resin and its proteolytic release. The protein modification of the phage capsid with appropriate binding motifs makes it possible to purify therapeutically bacteriophage strains using affinity chromatography. The proposed method is useful in the display of selected polypeptided on a bacteriophage capsid without the need to genetically modify the bacteriophage, and thus makes it possible to produce phage preparations for various uses using wild-type phages occurring naturally or others not additionally modified for phage-display purposes. | 11-07-2013 |
Agnieszka Korzeniowska-Kowal, Miekinia PL
Patent application number | Description | Published |
---|---|---|
20110008873 | PURIFIED BACTERIOPHAGE, ITS PREPARATION AND APPLICATION - A method of preparation of purified bacteriophage with increased antibacterial activity, in which from bacterial lysate of phages is obtained, advantageously in the presence of lysozyme, chelating factor and detergent, in a continuous manner with ultrafiltration on membranes, the phage containing high molecular mass preparation, devoid of bacterial cell wall and other contaminants, free of toxins and endotoxins, active in tests of bacterial lysis, which is characterized by chromatography HPLC, In SDS-PAGE electrophoresis, immunoblotting, biological tests of bacterial lysis, and is dedicated for phage therapy of bacterial infections and tumors and for production of phage deriving pharmaceutical preparations. | 01-13-2011 |
Agnieszka Kownacka, Poznan PL
Patent application number | Description | Published |
---|---|---|
20140005427 | NEW (TRIORGANOSILYL)ALKYNES AND THEIR DERIVATIVES AND A NEW CATALYTIC METHOD FOR OBTAINING NEW AND CONVENTIONAL SUBSTITUTED (TRIORGANOSILYL)ALKYNES AND THEIR DERIVATIVES | 01-02-2014 |
20140296468 | Hydrosilylation Reaction Catalysts and Curable Compositions and Methods for Their Preparation and Use - A composition contains (A) a hydrosilylation reaction catalyst and (B) an aliphatically unsaturated compound having an average, per molecule, of one or more aliphatically unsaturated organic groups capable of undergoing hydrosilylation reaction. The composition is capable of reacting via hydrosilylation reaction to form a reaction product, such as a silane, a gum, a gel, a rubber, or a resin. Ingredient (A) contains an iron-organosilicon ligand complex that can be prepared by reacting an iron carbonyl compound and an organosilicon ligand. | 10-02-2014 |
20150361111 | Catalytic method for obtaining substituted (triorganosilyl)alkynes and their derivatives - New (triorganosilyl)alkynes and their derivatives having general formula R | 12-17-2015 |
Agnieszka Krawczenko, Wroclaw PL
Patent application number | Description | Published |
---|---|---|
20130040315 | HUMAN AND MURINE STEM-CELL LINES: MODELS OF ENDOTHELIAL CELL PRECURSORS - The present invention relates to isolated human cells that are precursors of endothelial cells other than embryonic stem cells, to isolated murine cells that are precursors of endothelial cells, and to methods using same, In particular, the present invention relates to established cell lines of isolated human cells that are precursors of endothelial cells other than embryonic stem cells and established cell lines of isolated murine cells that are precursors of endothelial cells. The present invention can be used in particular in the medical and/or veterinary fields, in particular in the field of therapeutics and/or in the field of studies of cellular mechanisms. | 02-14-2013 |
Agnieszka Kurabe, Tokyo JP
Patent application number | Description | Published |
---|---|---|
20110181740 | IMAGE BLUR CORRECTION DEVICE, IMAGING LENS UNIT, AND CAMERA UNIT - An image blur correction device according to the present invention includes an a base ( | 07-28-2011 |
Agnieszka Lach, Chicago, IL US
Patent application number | Description | Published |
---|---|---|
20110136256 | METHODS AND KITS FOR DECREASING INTERFERENCES IN PLASMA OR SERUM CONTAINING ASSAY SAMPLES OF SPECIFIC BINDING ASSAYS - Methods and kits are provided for decreasing interferences and inaccuracies due to nonoptimal sample handling of blood samples in plasma or serum containing assay samples of specific binding assays by addition of a large polycation to the assay sample during the specific binding assay. | 06-09-2011 |
20130011827 | METHODS AND KITS FOR DECREASING INTERFERENCES IN PLASMA OR SERUM CONTAINING ASSAY SAMPLES OF SPECIFIC BINDING ASSAYS - Methods and kits are provided for decreasing interferences and inaccuracies due to nonoptimal sample handling of blood samples in plasma or serum containing assay samples of specific binding assays by addition of a large polycation to the assay sample during the specific binding assay. | 01-10-2013 |
Agnieszka Leszczuk, Wroclaw PL
Patent application number | Description | Published |
---|---|---|
20140346748 | Leveling Valve for Discharging and Supplying Fluid - A leveling valve for discharging and supplying air from and to a plurality of utilization elements comprises a valve disc arrangement configured to direct air between a source of pressurized air, an exhaust port, and the utilization elements. The valve disc arrangement comprises a first and a second valve disc, which are rotatable with respect to each other such that the valve is switchable between multiple switching positions, and, in some switching positions, either the source of pressurized air or the exhaust port are in fluid communication with the utilization elements. The valve discs provide a stepped increase in flow cross-section in a respective flow path to or from the utilization elements. The stepped increase is dependent on the angle of rotation between the valve discs. | 11-27-2014 |
Agnieszka Lindstaedt, Gdansk PL
Patent application number | Description | Published |
---|---|---|
20150259269 | Method for Isolation of 1,3-Propanediol from Post-Fermentation Broth Obtained by Bioconversion - A method for isolation of 1,3-propanediol from post-fermentation broth is disclosed. The method generally involves the following steps: (1) biomass removal from post-fermentation broth by one of the following methods: ultrafiltration, filtration, centrifugation or sedimentation; (2) 1,3-propanediol extraction with organic solvent mixture containing 2-butanone with high efficiency performed continuously or stepwise; (3) distillation under vacuum to obtain highly pure target product and (4) organic solvent recovery and recycling the solvent back into the process. The method is useful for recovering valuable 1,3-propanediol from aqueous solutions produced by fermentation. | 09-17-2015 |
Agnieszka Marcinowicz-Flick, Ames, IA US
Patent application number | Description | Published |
---|---|---|
20110053941 | IDO Inhibitors - Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein. | 03-03-2011 |
20130289083 | IDO Inhibitors - Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunsupression associated with an infectious disease, e.g., HIV-1 infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein. | 10-31-2013 |
Agnieszka Morawska, Skala PL
Patent application number | Description | Published |
---|---|---|
20150130099 | FORMATION METHOD OF A MIDDLE EAR PROSTHESIS - The process of preparing a middle ear prosthesis of polymeric material by injection moulding technology according to the presented invention is characterized by drying the thermoplastic polymer granules, preferably high density polyethylene or polyamide or polysulphone, at a temperature in the range of 60 to 150° C. for a period of 2 to 8 hours. Subsequently granules are plasticized and then injected at a temperature between 180 and 400° C. into the mold heated to a temperature between 60 and 150° C. Then obtained moulder is cooled and in the final stage it is hermetically packed in a vacuum and sterilized. In addition, the granules of the thermoplastic polymer composite are used, obtained by addition of bactericidal additive introduced into the thermoplastic polymer granules, preferably a silver powder with a particle size from 15 to 100 nm, in an amount of 0.1-3 wt %. | 05-14-2015 |
Agnieszka Ochenduszko, Tychy PL
Patent application number | Description | Published |
---|---|---|
20160082417 | PROCESS FOR THE PRODUCTION OF 1,3-BUTADIENE - The invention relates to the use of a novel silica-supported trimetallic (La/Zr/Zn) catalyst in the production of 1,3-butadiene from ethanol. The presence of lanthanum in the catalyst further comprising zirconium and zinc increases the catalyst's yield and selectivity to 1,3-butadiene. | 03-24-2016 |
Agnieszka Opalinska, Zyrardow PL
Patent application number | Description | Published |
---|---|---|
20090256083 | Zirconium Dioxide Luminescence Oxygen Sensor - A method of measuring oxygen partial pressure in gases, such as hot engine exhaust gases, uses a calibrated luminescence sensor and comprises the steps of bringing nanocrystalline zirconinum dioxide ZrO | 10-15-2009 |
Agnieszka Otrowicz, Wroclaw PL
Patent application number | Description | Published |
---|---|---|
20130295647 | METHOD OF PRODUCING BACTERIOPHAGE PREPARATIONS COMPRISING PURIFICATION USING AFFINITY CHROMATOGRAPHY - The proposed method facilitates the single-stage and at the same time effective purification of phage preparations for therapeutic uses, and facilitates the maintenance of bacteriophage antibacterial activity both in the case of displacement of the bacteriophage from the resin and its proteolytic release. The protein modification of the phage capsid with appropriate binding motifs makes it possible to purify therapeutically bacteriophage strains using affinity chromatography. The proposed method is useful in the display of selected polypeptided on a bacteriophage capsid without the need to genetically modify the bacteriophage, and thus makes it possible to produce phage preparations for various uses using wild-type phages occurring naturally or others not additionally modified for phage-display purposes. | 11-07-2013 |
Agnieszka Paradowska, Linden DE
Agnieszka Patkaniowska, New York, NY US
Patent application number | Description | Published |
---|---|---|
20120246747 | RNA-INTERFERENCE BY SINGLE-STRANDED RNA MOLECULES - The present invention relates to sequence and structural features of single-stranded (ss)RNA molecules required to mediate target-specific nucleic acid modifications by RNA-interference (RNAi), such as target mRNA degradation and/or DNA methylation. | 09-27-2012 |
20150096064 | RNA-INTERFERENCE BY SINGLE-STRANDED RNA MOLECULES - The present invention relates to sequence and structural features of single-stranded (ss)RNA molecules required to mediate target-specific nucleic acid modifications by RNA-interference (RNAi), such as target mRNA degradation and/or DNA methylation. | 04-02-2015 |
Agnieszka Piotrowska, Stare Babice PL
Patent application number | Description | Published |
---|---|---|
20140254612 | Method and filter for erasing hidden data - A method and a filter in telecommunication systems characterized in that the signal in the packet communications link is subject to normalization through restoration of default transport frame values, thus eliminating hidden data. | 09-11-2014 |
20140254797 | Method and filter for erasing hidden data - The application refers to a method and a filter of hidden data characterized by the fact that in order to eliminate the hidden data, the data signal is subject to operation of the degradation in a degradation function module. | 09-11-2014 |
20140359033 | Device and the method for sending personalised messages - The method for sending personalised messages, characterised by comprising steps in which a carrier is tagged, then a personalised message is saved on a server and attributed to the tagged carrier, next the personalised message is sent from the server in response to and in accordance with attribution to the tagged carrier. | 12-04-2014 |
Agnieszka Roginska, New York, NY US
Patent application number | Description | Published |
---|---|---|
20150201889 | SONIFICATION OF IMAGING DATA - Scans of brains result in data that can be challenging to display due to its complexity, multi-dimensionality, and range. Visual representations of such data are limited due to the nature of the display, the number of possible dimensions that can be represented visually, and the capacity of our visual system to perceive and interpret visual data. This paper describes the use of sonification to interpret brain scans and use sound as a complementary tool to view, analyze, and diagnose. The sonification tool may be used as a method to augment visual brain data display. | 07-23-2015 |
Agnieszka Romanik, Ostrow Mazowiecki PL
Patent application number | Description | Published |
---|---|---|
20140315247 | Expression Cassette, Use of the Expression Cassette, Expression Vector, Prokaryotic Host Cell Comprising Expression Vector, Bacterial Strain and a Method for Producing a Polypeptide - The subject matters of invention relate to expression cassette, use of the expression cassette, expression vector, prokaryotic host cell harbouring expression vector, bacterial strain, and method for producing a polypeptide. In more detail, the invention relate to stable expression of recombinant polypeptides, in systems with no need of using antibiotics. Particularly, stable expression of recombinant proteins obtained with the use of very efficient T7 polymerase/promoter system. | 10-23-2014 |
Agnieszka Safavi-Nab, Troisdorf DE
Patent application number | Description | Published |
---|---|---|
20150329826 | MATERIALS AND METHODS FOR CELL CULTURE - Methods and compositions for improved cell growth and serum-reduced or -free cell culture media. | 11-19-2015 |
Agnieszka Seyda, Belle Mead, NJ US
Patent application number | Description | Published |
---|---|---|
20110282324 | Multi-Chamber Therapeutic Cell Applicator Instrument - A surgical device comprises a housing, a plurality of media reservoirs, an end effector, and a pumping device. Each media reservoir is configured to receive at least one component of a tissue repair composition. The end effector is configured for insertion into a lumen to deliver a tissue repair composition into that lumen. The end effector has at least one fluid conduit and at least one orifice in communication with the fluid conduit. The pumping device is operable to urge a tissue repair composition comprising at least a portion of the contents of the plurality of media reservoirs through the fluid conduit of the end effector such that the tissue repair composition is expelled from the at least one orifice. The media reservoirs may contain medical fluid components such as viable cells and scaffold material to repair a fistula or address some other condition in a patient. | 11-17-2011 |
20130157365 | INDUCED PLURIPOTENT STEM CELLS FROM HUMAN UMBILICAL CORD TISSUE-DERIVED CELLS - We have disclosed an induced pluripotent stem cell and the method of preparing the induced pluripotent stem cell from a human umbilical cord tissue-derived cell. More particularly, we have disclosed a human umbilical cord tissue-derived iPS cell which may be differentiated into cells of ectoderm, mesoderm, and endoderm lineages. | 06-20-2013 |
20130157368 | INDUCED PLURIPOTENT STEM CELLS PREPARED FROM HUMAN KIDNEY-DERIVED CELLS - We have disclosed an induced pluripotent stem cell and the method of preparing the induced pluripotent stem cell from a human kidney-derived cell. More particularly, we have disclosed a human kidney-derived iPS cell which may be differentiated into cells of ectoderm, mesoderm, and endoderm lineages. | 06-20-2013 |
20130196431 | TISSUE ENGINEERED BLOOD VESSEL - Compositions and methods of using tissue engineered blood vessels to repair and regenerate blood vessels of patients with vascular disease are disclosed. | 08-01-2013 |
20130196439 | TISSUE ENGINEERED BLOOD VESSEL - Compositions and methods of using tissue engineered blood vessels to repair and regenerate blood vessels of patients with vascular disease are disclosed. | 08-01-2013 |
20130196440 | TISSUE ENGINEERED BLOOD VESSEL - Compositions and methods of using tissue engineered blood vessels to repair and regenerate blood vessels of patients with vascular disease are disclosed. | 08-01-2013 |
20130203168 | TISSUE ENGINEERED BLOOD VESSEL - Compositions and methods of using tissue engineered blood vessels to repair and regenerate blood vessels of patients with vascular disease are disclosed. | 08-08-2013 |
20130209418 | METHODS AND COMPOSITION RELATED TO BROWN ADIPOSE-LIKE CELLS - Methods and therapeutics are provided for treating diseases, including metabolic diseases and other weight-related disorders. Generally, methods for making brown adipose-like including culturing a population of artery-derived cells in adipogenic induction medium for a period of time and under conditions sufficient to increase expression of at least one adipocyte marker at a higher level as compared to untreated artery-derived cells are disclosed. Isolated artery-derived, ex vivo differentiated brown adipose-like cells are also provided, including pharmaceutical compositions and cell delivery systems thereof. In another embodiment, a method of treating a subject is disclosed that includes obtaining a population of artery-derived brown adipose-like cells and administering the brown adipose-like cells into a target region in the subject. | 08-15-2013 |
20150258142 | DECELLULARIZED PLEURAL MATRIX - The present invention pertains to the development of biologically derived extracellular matrices (ECM) derived from decellularized pleura tissue. Such matrices are useful in many clinical and therapeutic applications, including the repair, reconstruction, sealing, or joining of tissue, tendons, bones, and/or ligaments. In addition, the present invention features methods of making a biologically derived ECM derived from decellularized pleura tissue. The invention further features laminated ECM matrices. | 09-17-2015 |
Agnieszka Seyda, North Brunswick, NJ US
Patent application number | Description | Published |
---|---|---|
20140248326 | ENCAPSULATED KIDNEY TISSUE - Provided are therapeutic implants comprising renal tissue encapsulated within a polymer bead. Also disclosed are methods for treating a disease state in a subject comprising implanting within said subject a therapeutic implant comprising renal tissue encapsulated within a polymer bead. Also provided are methods for making a therapeutic implant comprising: providing renal tissue; mixing the renal tissue with a solution comprising a polymer, thereby forming a tissue-polymer suspension; extruding the tissue-polymer suspension into an bead-forming solution, thereby forming a therapeutic implant comprising beads of said polymer within which the renal tissue is encapsulated. | 09-04-2014 |
20140271778 | ENCAPSULATED KIDNEY TISSUE - Provided are therapeutic implants comprising renal tissue encapsulated within a polymer bead. Also disclosed are methods for treating a disease state in a subject comprising implanting within said subject a therapeutic implant comprising renal tissue encapsulated within a polymer bead. Also provided are methods for making a therapeutic implant comprising: providing renal tissue; mixing the renal tissue with a solution comprising a polymer, thereby forming a tissue-polymer suspension; extruding the tissue-polymer suspension into an bead-forming solution, thereby forming a therapeutic implant comprising beads of said polymer within which the renal tissue is encapsulated. | 09-18-2014 |
Agnieszka Seyda, New Brunswick, NJ US
Patent application number | Description | Published |
---|---|---|
20120315251 | POSTPARTUM CELLS DERIVED FROM UMBILICAL TISSUE AND METHODS OF MAKING AND USING THE SAME - Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described. | 12-13-2012 |
Agnieszka Sierzchala, Boulder, CO US
Patent application number | Description | Published |
---|---|---|
20080227964 | 2'-silyl containing thiocarbonate protecting groups for RNA synthesis - Nucleoside monomers, nucleic acids, e.g., oligonucleotides and polynucleotides, methods of making each, methods of deprotecting each, and the like are disclosed herein. Aspects of the invention include 2′ silyl containing thiocarbonate protecting groups. Corresponding compositions and methods are provided. | 09-18-2008 |
20090209479 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS - Aspects of the invention include 2′ protected nucleoside monomers that are protected at the 2′ site with thiocarbon protecting groups. Thiocarbon protecting groups of interest include thiocarbonate, thionocarbonate, dithiocarbonate groups, as well as thionocarbamate protecting groups. Aspects of the invention further include nucleic acids that include the protecting groups of the invention, as well as methods of synthesizing nucleic acids using the protecting groups of the invention. | 08-20-2009 |
20100076183 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS - A nucleoside monomer that is protected by a thionocarbamate protecting group is provided, as well as a method for making a polynucleotide that uses the same. Also provided is a polynucleotide synthesis method that employs a diamine to deprotect a protected polynucleotide. | 03-25-2010 |
20120238737 | THIOCARBON-PROTECTING GROUPS FOR RNA SYNTHESIS - Aspects of the invention include 2′ protected nucleoside monomers that are protected at the 2′ site with thiocarbon protecting groups. Thiocarbon protecting groups of interest include thiocarbonate, thionocarbonate, dithiocarbonate groups, as well as thionocarbamate protecting groups. Aspects of the invention further include nucleic acids that include the protecting groups of the invention, as well as methods of synthesizing nucleic acids using the protecting groups of the invention. | 09-20-2012 |
20120289691 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS - A method of deprotecting a solid support bound polynucleotide includes the step of contacting the polynucleotide with a composition comprising a diamine under conditions sufficient to deprotect the 2′-protected ribonucleotide residue. The solid support bound polynucleotide has at least one 2′-protected ribonucleotide residue, which has the following structure: | 11-15-2012 |
20160002282 | Protected Monomer and Method of Final Deprotection for RNA Synthesis - A method of deprotecting a solid support bound polynucleotide includes the step of contacting the polynucleotide with a composition comprising a diamine under conditions sufficient to deprotect the 2′-protected ribonucleotide residue. The solid support bound polynucleotide has at least one 2′-protected ribonucleotide residue, which has the following structure: | 01-07-2016 |
Agnieszka Sikorska, Trawniki PL
Patent application number | Description | Published |
---|---|---|
20150175944 | SANITARY APPLICATOR - The present invention is directed to a soluble applicator for applying self-adhesive composition onto the wall of sanitary elements, preferably a toilet basin. The invention is directed to a soluble applicator which may comprise at least one materials selected among monosaccharide or disaccharide based components, sugar alcohols, polyamide resin mixtures, soluble polymers or soluble gelling agents or mixtures thereof, to a sanitary product comprising such applicator and to a process for its manufacture. | 06-25-2015 |
20150275139 | NEW SANITARY COMPOSITION - The invention is directed to a self-adhesive sanitary composition for cleaning and/or disinfecting and/or deodorizing comprising an adhesion promoter comprising a mono, di, or oligosaccharide, preferably a monosaccharide or disaccharide and a surfactant, both in a high amount. | 10-01-2015 |
Agnieszka Sirko, Warszawa PL
Patent application number | Description | Published |
---|---|---|
20140255343 | DNA VACCINE, METHOD OF INDUCING THE IMMUNE RESPONSE, METHOD OF IMMUNISATION, ANTIBODIES SPECIFICALLY RECOGNISING THE H5 HAEMAGGLUTININ OF AN INFLUENZA VIRUS AND USE OF THE DNA VACCINE - The object of the invention is a DNA vaccine, method of inducing the immune response, antibodies specifically recognising the haemagglutinin H5 of an influenza virus and application of the DNA vaccine. According to the invention, one or two-fold immunisation of hens with DNA vaccine containing a cDNA encoding the modified H5 haemagglutinin HA protein, i.e. with the deletion of the cleavage site between HA subunits (this provides for greater safety of the vaccines). Moreover, the encoding region of the HA is modified in such a way that protein production in the bird cells should achieve maximal yield. The main modification is codon optimisation for the hens and deletion of the site of proteolytic cleavage between subunits HA1 and HA2. | 09-11-2014 |
Agnieszka Sosna, London GB
Patent application number | Description | Published |
---|---|---|
20110054846 | Monitoring the Performance of a Computer - A computer implemented method of monitoring the performance of a computer comprises monitoring the computer to determine the values of a plurality of activity metrics of the monitored computer. A weighted combination of functions of the determined values is calculated as a measure of performance of the monitored computer. The weighted combination may be a weighted combination of net values of activity metrics. In one embodiment, the net values are calculated as the said values of the plurality of activity metrics of the monitored computer excluding contributions to the values from the one or more predetermined activities. In another embodiment, the net values are calculated as follows. The total values of the respective activity metrics of the monitored computer are determined. The contribution(s) to the said total values of the said one or more predetermined activities are determined The said contribution(s) are subtracted from the said total values to provide net values. The weighted combination may be used to control power consumption or otherwise take action in relation to the computer. | 03-03-2011 |
Agnieszka Swiateck-Urban, Pittsburgh, PA US
Patent application number | Description | Published |
---|---|---|
20100197593 | Modulators of the ABC Transporter Family and Methods for their Use - An isolated factor derived from the bacterium | 08-05-2010 |
Agnieszka Szufarska, Gdansk PL
Patent application number | Description | Published |
---|---|---|
20110195719 | Configuration of Nodes for Local Data Transmission Which are Under an Overlay Wide Area Macro Network Operated on the Same Frequency Layer - At a node for local data transmission which is under an overlay wide area macro network operated on the same frequency layer, conditions of a wide area cell of the overlay wide area macro network are obtained, wherein the wide area cell is measured as a cell with a certain received signal level at a location of the node. Based on the conditions of the wide area cell, an allocation of channels for local area data transmission from the node is set such that interference of the channels for the local area data transmission with allocated wide area channels of the wide area cell is avoided or minimized. | 08-11-2011 |
20110242965 | Automatic connection re-establishment using escape carrier - In one exemplary aspect of this invention a method includes receiving at a user equipment from a wide area network access node information identifying at least one predetermined radio frequency carrier; initiating, in response to a presence of an interferer on a radio frequency carrier that is being used for a current connection between the user equipment and the network access node, a connection re-establishment procedure, where the interferer has the potential to cause a radio link failure of the current connection on the radio frequency carrier; and transmitting a connection re-establishment request to the network access node on the predetermined radio frequency carrier. The interferer can be a closed subscriber group network access node that the user equipment is not authorized to gain access to. | 10-06-2011 |
20110250881 | Apparatus, Method, System and Program for Power Control or Power Setting - Embodiments provide an apparatus, method, product and storage medium for controlling or setting a transmit power of a femto cell depending on a received power of at least one neighbouring macro cell. | 10-13-2011 |
20120202490 | Method and Apparatus for Determining a Time Interval at an Access Node for Radio Measurements - A method includes determining at least one time interval for an access node of a group of neighboring access nodes. The at least one time interval is one in which said access node has substantially no transmission and one or more other access nodes of said group transmit. The method further includes performing, by said access node, radio measurements in said at least one determined time interval of said one or more other access nodes of said group which transmit and configuring radio resources in dependence on said radio measurements. | 08-09-2012 |
20120252524 | Uplink Power Control for Lower Power Nodes - A method and an apparatus are described, in which a transmission power related parameter used for determining an uplink transmission power for a first cell based on the relational parameter, which indicates a relationship between the first cell and the second cell. | 10-04-2012 |
20130100836 | Allocating One or More Resources (e.g. carriers) to a Network Element (e.g. HeNB) in a Communication System - A method of allocating one or more carriers such as frequencies, to a network element (e.g. HeNBs) in a communication system, in particular a heterogeneous communication system including selecting at least one neighbouring network element (e.g. a macro base station), measuring a parameter (e.g. RSRP) from the one neighbouring network element; determining whether said parameter is above a threshold; and allocating carrier(s) to said network element as a result. | 04-25-2013 |
20130109395 | Proximity report after a change of frequency | 05-02-2013 |
20130109429 | Interference Management | 05-02-2013 |
20130136057 | Base Station Aided Synchronization - An apparatus, method and computer program product include requesting a physical identifier of a communication base station having a preset hierarchical distance to a communication core network from a first communication base station having a higher hierarchical distance than the preset hierarchical distance, based on a connection on one of an interface between a communication base station having a higher hierarchical distance than the preset hierarchical distance and the communication core network and an interface between two communication base stations both having a higher hierarchical distance than the preset hierarchical distance. Prior to the requesting, an initial synchronization with a neighbor base station can be established. After the requesting, an accurate synchronization with the overly base station based on the obtained physical identifier can be established. | 05-30-2013 |
20130137478 | Power Control - The invention relates to apparatuses, a method, system, computer program, computer program product and computer-readable medium. | 05-30-2013 |
20130242782 | Method and Apparatus for Adjusting Transmission Power in a Radio System - The invention relates to a method and apparatus to adjust transmission of a closed subscriber group node for improving radio coverage when the signal power received from the strongest co-channel open-access cell e.g. macro cell and the handover rate in the node does not fulfil set conditions. | 09-19-2013 |
20130265939 | Network Element and Method of Communication in a Wireless Communication Network - A network element for a communication network, wherein the network element includes an input interface adapted to receive a measurement report associated with a further network element, wherein the measurement report includes an identifier value identifying the further network element and a first value of a characteristic feature, and a comparing unit adapted to compare the first value with a second value of the same characteristic feature stored for said identifier value in the network element. Furthermore, the network element includes a signal generating unit adapted to generate a signal in case the comparison of the first value and the second value indicates that an appropriately defined distance between the first value and the second value is above a predetermined threshold. | 10-10-2013 |
Agnieszka Szufarska, Wroclaw PL
Patent application number | Description | Published |
---|---|---|
20150016365 | Carrier Aggregation Optimization - The present invention provides a method, apparatus and a computer program product for carrier aggregation optimization. The present invention includes receiving, at a base station, information from another base station regarding usage of PCell and SCell per carrier at the another base station, analyzing, at the base station, the received information, configuring, at the base station, PCells and SCells for user equipment served by the base station based on the analysis of the received information. | 01-15-2015 |
Agnieszka Szydelko, Dzierzoniow PL
Patent application number | Description | Published |
---|---|---|
20140205839 | PURE ALBUMIN AND ITS METHOD OF PREPARATION AND DETECTION - The subject of the present invention is a pure monomeric bovine serum albumin, a method of producing it characterised by the use column chromatography in resin and a method of identifying it using dynamic light scattering. | 07-24-2014 |
Agnieszka Szydlik, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20150080559 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives - Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses. | 03-19-2015 |
Agnieszka Szymanska-Michalak, Sroda Wlkp PL
Patent application number | Description | Published |
---|---|---|
20130316970 | NUCLEOTIDE ANALOGUE, METHOD OF SYNTHESIS OF NUCLEOTIDE ANALOGUE, USE OF NUCLEOTIDE ANALOGUE, ANTIVIRAL PRO-NUCLEOTIDE, PHARMACEUTICAL COMPOSITION - The object of the invention are nucleotide analogues, antiviral pro-nucleotides, a use of nucleotide analogues and pharmaceutical composition, a phosphorylating agent for synthesis of nucleotide analogue, and a method of synthesis of nucleotide analogue. More precisely, the invention applies to the new group of nucleotide analogues and their use in partial or complete inhibition of human immunodeficiency virus (HIV). | 11-28-2013 |
Agnieszka Thonet, Meylan FR
Patent application number | Description | Published |
---|---|---|
20130297739 | UTILIZING CONTENT VIA PERSONAL CLOUDS - Example embodiments disclosed herein relate to processing content using a personal cloud. One of a plurality of content items respectively associated with a plurality of devices of a personal cloud is determined. A processing to be performed on the one content item is determined. The processed version of the one content item is determined. | 11-07-2013 |
Agnieszka Turowska, Giessen DE
Patent application number | Description | Published |
---|---|---|
20150260728 | Method for Diagnosing a Molecular Phenotype of a Patient Suffering From an Illness Accompanied by Chronic Inflammation - Chronic inflammation is an increasing medical problem area of high socioeconomic significance. The invention relates to a method and a kit for diagnosing a molecular phenotype of a patient suffering from an illness accompanied by chronic inflammation, and to a medicament for treating such a patient. To that end, the gene expression of GATA-3 and/or Tbet in a biological isolate of the patient is measured and used for association with a molecular phenotype of the illness. | 09-17-2015 |
Agnieszka Wojtalewicz-Kasprzak, Emlichheim DE
Patent application number | Description | Published |
---|---|---|
20090162267 | Method for Recovery of Rare Earths from Fluorescent Lamps - Method for recovery of rare earths from fluorescent lamps. The method comprises six steps. The individual process steps are: Mechanical separation of coarse components. Separation of the halophosphate. Extraction in acids of easily soluble rare-earth fluorescent substances (mainly Y, Eu-oxide) Extraction in acids of rare-earth fluorescent substances which dissolve with difficulty (for example rare-earth phosphates) Breakdown of the remaining components which contain rare earths (for example rare-earth-aluminates) Final treatment. | 06-25-2009 |
20120027651 | METHOD FOR RECOVERY OF RARE EARTHS FROM FLUORESCENT LAMPS - Method of recovery of rare earths from fluorescent lamps. The method comprises six steps. The individual process steps are: Mechanical separation of coarse components. Separation of the halophosphate. Extraction in acids of easily soluble rare-earth fluorescent substances (mainly Y, Eu-oxide) Extraction in acids of rare earth fluorescent substances which dissolve with difficulty (for example rare-earth phosphates) Breakdown of the remaining components which contain rare earths (for example rare-earth-aluminates) Final treatment. | 02-02-2012 |
Agnieszka Wojtkielewicz, Bialystok PL
Patent application number | Description | Published |
---|---|---|
20110311652 | Novel Saponin Compounds, Methods of Preparation Thereof, Use Thereof and Pharmaceutical Compositions - This invention relates to novel saponin compounds of formula II wherein MBz denotes p-methoxybenzoyl, and R is selected from the group comprising C | 12-22-2011 |